The lowest total score was 16points, completelynormal; over 16 points representedwithfunctionalreduction to differentdegree; the highest score was 64 points.
Eli Lilly, however, is proceeding with its solanezumab compound, which slowed cognitive decline in patients with mild disease, but showed no statistically significant reduction in functional decline ( see this).